The chaotic collapse of Christian Eriksen on the pitch in Copenhagen was a stark reminder of the fragility of life. But the real story, for those of us who follow the bottom line, is the piece of kit that saved him: the implantable cardioverter-defibrillator (ICD). A marvel of British medical engineering, yes. But also a case study in the collision of public health spending and market efficiency.
The ICD is a battery-powered device, about the size of a pocket watch, that monitors the heart’s rhythm. When it detects a dangerous arrhythmia, it delivers a jolt to restore normal function. Eriksen’s device – likely a model from Medtronic or Boston Scientific – is the product of decades of R&D, much of it funded through the UK’s National Health Service and taxpayer-backed research grants. The total cost to the NHS for an ICD implantation runs around £25,000, including the device, surgery, and follow-up care. For elite athletes like Eriksen, the price is higher: private clinics, bespoke programming, and constant monitoring.
But here’s the rub: the ICD is a one-shot solution for a specific condition. It’s not a cure, it’s a patch. Eriksen has hypertrophic cardiomyopathy, a genetic condition that thickens the heart muscle and increases the risk of sudden cardiac arrest. The device is a Band-Aid, not a vaccine. And it comes with its own liabilities: battery replacement every 5-7 years, risk of infection, and the psychological burden of living with a ticking electric box in your chest.
Let’s talk about the cost-benefit analysis. The NHS spends roughly £1.5 billion annually on cardiovascular surgery and devices. That’s 4% of its entire budget. For that money, we could fund 30,000 hip replacements or 150,000 MRI scans. The opportunity cost is immense. And yet, we celebrate a single case of a footballer saved by this technology, ignoring the thousands of patients who never get the device because the health service rations them based on age or lifestyle. The National Institute for Health and Care Excellence (NICE) guidelines are clear: ICDs are reserved for those with a high risk of fatal arrhythmia, not for every scare. Eriksen’s survival is a triumph for him, but a statistical outlier.
The market for these devices is dominated by US and European firms. British manufacturers like Oxford Metrics have some patents, but our real contribution is the clinical research infrastructure. The NHS’s massive datasets have allowed companies to refine algorithms, predict arrhythmias, and reduce false shocks. But that data is a public asset, given away cheaply to private firms. McKinsey estimates the global ICD market will hit £15 billion by 2026. The UK’s share of that pie is negligible. We are the R&D lab, not the factory floor.
This also raises a question about capital flight. Eriksen, a Dane, chose to be treated in London at the private Harley Street Clinic. That’s fine: money flows where expertise is. But the expertise itself was built on public money. The cardiologists who saved him trained at NHS hospitals. The device protocols were developed using NHS patients. The entire ecosystem is a subsidy for the wealthy. Every time a foreign oligarch flies in for a heart procedure, we are exporting a public good at private rates. The Treasury sees the VAT, but the real cost is the hollowing out of the NHS’s own capacity.
And let’s not ignore the inflation of expectations. Every headline like this one creates demand. Patients now expect the NHS to deliver miracle devices despite a decade of underinvestment. The waiting list for ICDs has grown 22% since 2019. Gilt yields are rising, meaning the government pays more for the debt it issues to fund the NHS. The fiscal arithmetic does not add up.
Central bank policy compounds the problem. The Bank of England’s quantitative easing programme flooded the economy with cheap money, inflating asset prices. The wealthy – people like Eriksen – have seen their holdings rise. They can afford private medical care. The rest rely on a state that is being squeezed by rising interest rates. The Bank’s base rate of 5.25% makes the government’s debt service burden heavier, leaving less for real investment in medical innovation.
So, yes, British medical expertise is in the spotlight. But it is a spotlight that illuminates a system of perverse incentives: public funding for private gain, life-saving technology for the few, and fiscal strain for the many. Eriksen’s heart device is a triumph of engineering. As an economic model, it is a failure.
